Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals has earned a $1.5 million milestone payment from TAP Pharmaceutical Products with the submission of an investigational new drug application for osteoporosis therapy, LGD2941, to the FDA.
Subscribe to our email newsletter
The investigational new drug (IND) filing seeks to evaluate LGD2941 as a potential new therapy for the treatment of osteoporosis and frailty.
LGD2941 is a selective androgen receptor modulator (SARM) developed as a result of a collaboration between Ligand and TAP. Ligand would receive additional milestones and up to double-digit royalty payments on sales if the compound continues through the development process and receives marketing approval.
In July 2004, Ligand earned a $1 million milestone with TAP’s selection of a second SARM as a clinical candidate. TAP has also selected several other research compounds for further research and testing. In December 2004, Ligand announced the extension of the collaboration agreement with TAP through June 2006.
Under the terms of the agreement, TAP has been granted exclusive worldwide rights to manufacture, develop, and sell selected products resulting from the collaboration in its field, including treatment and prevention of hypogonadism, male and female sexual dysfunction, female and male osteoporosis, frailty, male hormonal therapy and all other indications not retained by Ligand.